Cancer immunotherapy: present scenarios and the future of immunotherapy

被引：3
作者：
Chakraborty, Dwaipayan [1 ]
Pati, Subhadip [1 ]
Bose, Sayantan [1 ]
Dhar, Subhanki [1 ]
Dutta, Saikat [1 ]
Sa, Gaurisankar [1 ]
机构：
[1] Bose Inst, Div Mol Med, P-1-12,CIT Scheme 7 M, Kolkata 700054, India
来源：
NUCLEUS-INDIA | 2019年 / 62卷 / 02期
关键词：
Cancer immunotherapy; T regulatory cell; B regulatory cell; CAR T cells; Immunoediting; REGULATORY T-CELLS; B-CELLS; DENDRITIC CELLS; BREAST-CANCER; TUMOR; ANTIBODY; VACCINATION; IPILIMUMAB; RESPONSES; CTLA-4;
D O I：
10.1007/s13237-019-00273-4
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
One of the major emerging modes of treatment for cancer patients in the current healthcare systems has been immunotherapy. Various approaches of immunotherapy have been proved to be useful against tumor progression in laboratory settings. Few have also been showing promising results in clinical trials. However, many clinical trials have also pointed out the adverse side effects of immunotherapy on tumor patients. In this context, we discuss about the success and failures of the present modes of immunotherapy available to patients and also about the emerging target points that are coming up and may be crucial in the success of future immunotherapy. The upcoming researches involving new players in the immunotherapy arena like Breg and Treg and how combinatorial therapies will be needed to counter the side effects that are exhibited by the present techniques of immunotherapy have been discussed in the review. This review will provide a broad picture of the current scenario of cutting edge immunotherapy and the newer methods that can be utilized to prevent the failures and ensure success in future clinical trials involving immunotherapy.
引用
收藏
页码：143 / 154
页数：12
相关论文
共 105 条
[1]   Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer [J].
Al-Shibli, Khalid I. ;
Donnem, Tom ;
Al-Saad, Samer ;
Persson, Magnus ;
Bremnes, Roy M. ;
Busund, Lill-Tove .
CLINICAL CANCER RESEARCH, 2008, 14 (16) :5220-5227
[2]  
Amaria RN, 2015, J CLIN ONCOL, V33
[3]  
Antonia SJ, 2014, J CLIN ONCOL, V32, P74
[4]  
Au KM, 2018, ACS NANO, V83, P48
[5]   Advancing Clinical Trials to Streamline Drug Development [J].
Bates, Susan E. ;
Berry, Donald A. ;
Balasubramaniam, Sanjeeve ;
Bailey, Stuart ;
LoRusso, Patricia M. ;
Rubin, Eric H. .
CLINICAL CANCER RESEARCH, 2015, 21 (20) :4527-4535
[6]   Essential role of mitochondrial energy metabolism in Foxp3+ T-regulatory cell function and allograft survival [J].
Beier, Ulf H. ;
Angelin, Alessia ;
Akimova, Tatiana ;
Wang, Liqing ;
Liu, Yujie ;
Xiao, Haiyan ;
Koike, Maya A. ;
Hancock, Saege A. ;
Bhatti, Tricia R. ;
Han, Rongxiang ;
Jiao, Jing ;
Veasey, Sigrid C. ;
Sims, Carrie A. ;
Baur, Joseph A. ;
Wallace, Douglas C. ;
Hancock, Wayne W. .
FASEB JOURNAL, 2015, 29 (06) :2315-2326
[7]   Regulatory B cells play a key role in immune system balance [J].
Berthelot, Jean-Marie ;
Jamin, Christophe ;
Amrouche, Kahina ;
Le Goff, Benoit ;
Maugars, Yves ;
Youinou, Pierre .
JOINT BONE SPINE, 2013, 80 (01) :18-22
[8]   Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L [J].
Bodogai, Monica ;
Chang, Catalina Lee ;
Wejksza, Katarzyna ;
Lai, Jinping ;
Merino, Maria ;
Wersto, Robert P. ;
Gress, Ronald E. ;
Chan, Andrew C. ;
Hesdorffer, Charles ;
Biragyn, Arya .
CANCER RESEARCH, 2013, 73 (07) :2127-2138
[9]   Curcumin and tumor immune-editing: resurrecting the immune system [J].
Bose, Sayantan ;
Panda, Abir Kumar ;
Mukherjee, Shravanti ;
Sa, Gaurisankar .
CELL DIVISION, 2015, 10
[10]   Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity [J].
Carmi, Yaron ;
Spitzer, Matthew H. ;
Linde, Ian L. ;
Burt, Bryan M. ;
Prestwood, Tyler R. ;
Perlman, Nicola ;
Davidson, Matthew G. ;
Kenkel, Justin A. ;
Segal, Ehud ;
Pusapati, Ganesh V. ;
Bhattacharya, Nupur ;
Engleman, Edgar G. .
NATURE, 2015, 521 (7550) :99-U254
12345678910